These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 15999492)
1. [P53 expression and its clinical significance in prostatic carcinoma]. Jiang T; Jiang H; Song XS; Li XC; Li QL Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492 [TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma]. Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337 [TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Zhigang Z; Wenlv S Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669 [TBL] [Abstract][Full Text] [Related]
4. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Sasor A; Wagrowska-Danilewicz M; Danilewicz M Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901 [TBL] [Abstract][Full Text] [Related]
5. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance]. Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704 [TBL] [Abstract][Full Text] [Related]
6. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues]. Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871 [TBL] [Abstract][Full Text] [Related]
7. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661 [TBL] [Abstract][Full Text] [Related]
8. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738 [TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Zhao Z; Liu J; Li S; Shen W Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463 [TBL] [Abstract][Full Text] [Related]
10. [Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma]. Gu XJ; Lu JL; Lai RS; Zhang YD; Zhang P; Lu ZJ; Zhu QY Zhonghua Nan Ke Xue; 2006 Apr; 12(4):340-2. PubMed ID: 16683569 [TBL] [Abstract][Full Text] [Related]
11. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. Yu DS; Hsieh DS; Chen HI; Chang SY J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236 [TBL] [Abstract][Full Text] [Related]
12. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729 [TBL] [Abstract][Full Text] [Related]
13. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494 [TBL] [Abstract][Full Text] [Related]
14. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356 [TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309 [TBL] [Abstract][Full Text] [Related]
17. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585 [TBL] [Abstract][Full Text] [Related]
18. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
19. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Arai T; Fujita K; Fujime M; Irimura T Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558 [TBL] [Abstract][Full Text] [Related]
20. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance]. Liu BQ; Wu YD; Wei JX; Zhang T; Liu RL; Ma TX Zhonghua Nan Ke Xue; 2007 Nov; 13(11):997-1001. PubMed ID: 18077911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]